The HLA-Cw*06 allele may predict the response to methotrexate (MTX) treatment in Chinese arthritis-free psoriasis patients

Mao, Manyun; Kuang, Yehong; Chen, Menglin; Yan, Kexiang; Lv, Chenzhi; Li, Panpan; Lü, Yan; Chen, Xiang; Zhu, Wu; Chen, Wangqing

doi:10.1007/s00403-022-02498-x

Cited by 4 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study on a South Indian Tamil population found that the HLA-Cw*06-positive allele and rs3761548 of the FOXP3 gene were independent genetic predictors for the clinical response to methotrexate [ 44 ]. Other studies have validated the association between the HLA-Cw*06-positive allele and a greater response to this drug in English [ 45 ] and Chinese populations [ 46 ]. In this last study, a synergistic effect between the HLA-Cw*06-positive allele and the ABCB1 rs1045742 SNP was also demonstrated [ 46 ].…”

Section: Therapeutic Optionsmentioning

confidence: 99%

“…Other studies have validated the association between the HLA-Cw*06-positive allele and a greater response to this drug in English [ 45 ] and Chinese populations [ 46 ]. In this last study, a synergistic effect between the HLA-Cw*06-positive allele and the ABCB1 rs1045742 SNP was also demonstrated [ 46 ]. Conversely, Chen et al observed a worse response to methotrexate in psoriasis patients with the rs1045642 variant [ 47 ].…”

Section: Therapeutic Optionsmentioning

confidence: 99%

See 1 more Smart Citation

Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine

Berna-Rico,

Perez-Bootello,

Abbad-Jaime de Aragon

et al. 2023

IJMS

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory disease with an established genetic background. The HLA-Cw*06 allele and different polymorphisms in genes involved in inflammatory responses and keratinocyte proliferation have been associated with the development of the disease. Despite the effectiveness and safety of psoriasis treatment, a significant percentage of patients still do not achieve adequate disease control. Pharmacogenetic and pharmacogenomic studies on how genetic variations affect drug efficacy and toxicity could provide important clues in this respect. This comprehensive review assessed the available evidence for the role that those different genetic variations may play in the response to psoriasis treatment. One hundred fourteen articles were included in this qualitative synthesis. VDR gene polymorphisms may influence the response to topical vitamin D analogs and phototherapy. Variations affecting the ABC transporter seem to play a role in methotrexate and cyclosporine outcomes. Several single-nucleotide polymorphisms affecting different genes are involved with anti-TNF-α response modulation (TNF-α, TNFRSF1A, TNFRSF1B, TNFAIP3, FCGR2A, FCGR3A, IL-17F, IL-17R, and IL-23R, among others) with conflicting results. HLA-Cw*06 has been the most extensively studied allele, although it has only been robustly related to the response to ustekinumab. However, further research is needed to firmly establish the usefulness of these genetic biomarkers in clinical practice.

show abstract

Section: Therapeutic Optionsmentioning

confidence: 99%

Section: Therapeutic Optionsmentioning

confidence: 99%

Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine

Berna-Rico,

Perez-Bootello,

Abbad-Jaime de Aragon

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Methotrexate encompasses the largest number of pharmacogenetic studies compared to the rest of the conventional therapies, focusing on disease-associated loci, as is the case with the ANXA6 rs11960458 SNP [ 63 ]. Stratification of individuals according to the HLA-C allele status revealed significant associations between HLA-Cw6 + patients and treatment outcomes in arthritis-free psoriasis patients [ 64 , 65 ], while the CsA-associated ABCB1 rs1045642 SNP was additionally incorporated into significant predictive models [ 65 ]. In contrast, Yan et al failed to validate the pharmacogenetic role of the HLA-Cw6 allele in 90 Chinese patients, reporting, however, associations between the LCE3D rs4112788 and TNIP1 rs10036748 SNPs and responses to therapy [ 66 ].…”

Section: Traditional Therapiesmentioning

confidence: 99%

Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine

Antonatos

Asmenoudi

Panoutsopoulou

et al. 2023

IJMS

View full text Add to dashboard Cite

The emergence of high-throughput approaches has had a profound impact on personalized medicine, evolving the identification of inheritable variation to trajectory analyses of transient states and paving the way for the unveiling of response biomarkers. The utilization of the multi-layered pharmaco-omics data, including genomics, transcriptomics, proteomics, and relevant biological information, has facilitated the identification of key molecular biomarkers that can predict the response to therapy, thereby optimizing treatment regiments and providing the framework for a tailored treatment plan. Despite the availability of multiple therapeutic options for chronic diseases, the highly heterogeneous clinical response hinders the alleviation of disease signals and exacerbates the annual burden and cost of hospitalization and drug regimens. This review aimed to examine the current state of the pharmaco-omic approaches performed in psoriasis, a common inflammatory disease of the skin. We sought to identify central studies that investigate the inter-individual variability and explore the underlying molecular mechanisms of drug response progression via biological profiling in psoriatic patients administered with the extended therapeutic armamentarium of psoriasis, incorporating conventional therapies, small molecules, as well as biological drugs that inhibit central pathogenic cytokines involved in the disease pathogenesis.

show abstract

“…gastrointestinal disorders. Regarding systemic treatment, methotrexate (MTX) remains the first choice for cost-effectiveness and long-term record in China [13]. However, MTX is accompanied by side effects such as gastrointestinal discomfort, liver and kidney function damage, bone marrow suppression, and pulmonary fibrosis [14].…”

Section: Bac Restrains the Abnormal Proliferation But Not The Surviva...mentioning

confidence: 99%

“…Local treatment is not suitable for all patients with psoriasis for several reasons: low skin retention rate of drug preparations, poor skin permeability, oily texture of local carriers, and gastrointestinal disorders. Regarding systemic treatment, methotrexate (MTX) remains the first choice for Molecules 2023, 28, 4473 2 of 11 cost-effectiveness and long-term record in China [13]. However, MTX is accompanied by side effects such as gastrointestinal discomfort, liver and kidney function damage, bone marrow suppression, and pulmonary fibrosis [14].…”

Section: Introductionmentioning

confidence: 99%

Benzoylaconitine Alleviates Progression of Psoriasis via Suppressing STAT3 Phosphorylation in Keratinocytes

Li,

Guo,

Wang

et al. 2023

Molecules

View full text Add to dashboard Cite

Psoriasis is a chronic and multifactorial skin disease which is caused by inflammatory infiltrates, keratinocyte hyperproliferation, and accumulation of immune cells. As part of the Aconitum species, Benzoylaconitine (BAC) shows potential antiviral, anti-tumor, and anti-inflammatory effects. In this study, we investigated the effects and mechanisms of BAC on tumor necrosis factor-alpha (TNF-α)/LPS-induced HaCaT keratinocytes in a imiquimod(IMQ)-induced mice model. The results showed that BAC could relieve the symptoms of psoriasis by inhibiting cell proliferation, the release of inflammatory factors, and the accumulation of Th17 cells, while no obvious effect on cell viability and safety was observed both in vitro and in vivo. Additionally, BAC can markedly inhibit the protein and mRNA levels of inflammatory cytokines in TNF-α/LPS-induced HaCaT keratinocytes by inhibiting the phosphorylation of STAT3. In brief, our data indicated that BAC could alleviate the progression of psoriasis and may be a potential therapeutic agent for treating psoriasis in clinical practice.

show abstract

The HLA-Cw*06 allele may predict the response to methotrexate (MTX) treatment in Chinese arthritis-free psoriasis patients

Cited by 4 publications

References 33 publications

Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine

Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine

Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine

Benzoylaconitine Alleviates Progression of Psoriasis via Suppressing STAT3 Phosphorylation in Keratinocytes

Contact Info

Product

Resources

About